8-K: Lyell Immunopharma Holds Annual Meeting, Elects Directors
Annual Meeting of Stockholders Results
Lyell Immunopharma, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of Class II directors and the ratification of its independent auditor.
Summary
- Lyell Immunopharma, Inc. held its 2026 annual meeting of stockholders on June 10, 2026.
- A quorum was established with 67.31% of outstanding common stock represented.
- Stockholders voted on three proposals: election of Class II directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of executive compensation.
- The election of Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin as Class II directors was approved.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The compensation of named executive officers was approved on an advisory basis.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports on routine corporate governance matters without new financial or strategic information.
Positives
- A significant majority of stockholders (67.31%) participated in the annual meeting, indicating strong engagement.
- The election of directors and ratification of the auditor passed with substantial support.
- The company successfully held its annual meeting virtually, demonstrating operational adaptability.
Future Outlook
No specific forward-looking statements or guidance were provided in this filing, which pertains to the results of the annual meeting.
Industry Context
StockSavvy.ai notes that the smooth execution of annual meetings and director elections is a standard governance practice for publicly traded companies, reflecting operational stability and shareholder engagement.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class II Director | N/A | Richard Klausner, M.D. | June 10, 2026 | Election by stockholders |
| Class II Director | N/A | Otis Brawley, M.D. | June 10, 2026 | Election by stockholders |
| Class II Director | N/A | William Rieflin | June 10, 2026 | Election by stockholders |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Election | Election of Class II directors to hold office until the Companys 2029 annual meeting of stockholders. | June 10, 2026 | Standard election process to ensure board continuity and oversight. |
| Auditor Ratification | Ratification of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2026. | June 10, 2026 | Confirms auditor independence and reliance on their financial reporting oversight. |
| Executive Compensation Approval | Advisory approval of the compensation of the Companys named executive officers. | June 10, 2026 | Provides shareholder feedback on executive pay practices. |
Stakeholder Impact
- Shareholders: The election of directors and advisory vote on executive compensation directly involve shareholder rights and influence corporate governance.
- Employees: Board composition and executive compensation policies can indirectly impact employee morale and company direction.
- Auditors: The ratification of Ernst & Young LLP confirms their role in providing assurance on the company's financial statements.
Key Dates
| Date | Description |
|---|---|
| April 14, 2026 | Record date for the Annual Meeting. |
| April 24, 2026 | Date of filing of the Company's definitive proxy statement on Schedule 14A. |
| June 10, 2026 | Date of the 2026 annual meeting of stockholders. |
| June 15, 2026 | Date of the report signing. |
| December 31, 2026 | Fiscal year end for which Ernst & Young LLP was appointed as auditor. |
| 2029 | Term end for elected Class II directors. |
Keywords
Lyell Immunopharma, Annual Meeting, Stockholder Vote, Director Election, Independent Auditor, Executive Compensation, Corporate Governance, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.